The Impact of Changes in Depression on Cardiovascular Outcomes in Patients With Coronary Heart Disease

Autor: Vatsa, Nishant, Bennett, Josiah, Vatsa, Sonika, Rahbar, Alireza, Gold, Daniel A., Jain, Vardhmaan, Gold, Matthew E., Razavi, Alexander, Yadalam, Adithya, Desai, Shivang, Owais, Muhammad, Hartsfield, Joy D., Ko, Yi-An, Sperling, Laurence, Vaccarino, Viola, Mehta, Puja K., Quyyumi, Arshed A.

Publikováno v: In JACC: Advances November 2024 3(11)

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.

Autor: Bailey SR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Vatsa S; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Berger TR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts., Wehrli M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Silva H; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Lindell KA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Demato A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Gallagher KME; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.

Publikováno v: Blood cancer discovery [Blood Cancer Discov] 2022 Mar 01; Vol. 3 (2), pp. 136-153.